The Phase 3 study of Covaxin enlisted 25,800 participants between the age of 18-98 years, including a 10 per cent population over the age of 60.
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.